Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,400,000 shares, an increase of 8.5% from the August 31st total of 1,290,000 shares. Based on an average daily trading volume, of 434,700 shares, the short-interest ratio is currently 3.2 days.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $0.23 on Tuesday. Brainstorm Cell Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $0.79. The company’s 50 day moving average price is $0.30 and its two-hundred day moving average price is $0.41. The firm has a market capitalization of $16.14 million, a price-to-earnings ratio of -0.72 and a beta of 0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). During the same quarter in the prior year, the firm posted ($0.27) earnings per share. As a group, equities research analysts predict that Brainstorm Cell Therapeutics will post -0.19 EPS for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. 14.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on BCLI. Maxim Group upgraded Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Thursday, July 11th. StockNews.com initiated coverage on Brainstorm Cell Therapeutics in a report on Tuesday. They issued a “hold” rating for the company.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.